{"name":"Binhui Biopharmaceutical Co., Ltd.","slug":"binhui-biopharmaceutical-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"OH2 injection","genericName":"OH2 injection","slug":"oh2-injection","indication":"Non-small cell lung cancer, PD-L1 positive","status":"phase_3"}]}],"pipeline":[{"name":"OH2 injection","genericName":"OH2 injection","slug":"oh2-injection","phase":"phase_3","mechanism":"OH2 injection is a monoclonal antibody that targets the PD-1 receptor.","indications":["Non-small cell lung cancer, PD-L1 positive","Head and neck squamous cell carcinoma"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMisgJBVV95cUxNY3A2YmU5QTE4OEpCUG1XdmFQT1lpUC1ieVgzX3hIWi1yWUFPVTBxWURCdFljZzRWWk0tbk45VnBoUHp2SWVyZXFzMVhrX3NKS2liTkNtb0llZnlxdkdrSHBzWUhncVZvTFkwcnlPbHU5R0MwTV9WMmdEWDB3QVlXcGJhTzZuVkNQa2xKb0J6dU1FXy1QU1VGSmhZaDlYbWdpVUlGWm0ybkhQbjVWaUk3T1JGLURzZ2xKckN4UFJzRTBfbG1tYTlWekN5NkJZQ2ZNLVBGbEl1N0lBMDVMM1hldVlwTVhZRjNnbWZXT21DbzlTZGJfczdDTGctajZHeUFibUJ6NlBqX2t4M0hBWWliNUZISnlObTRBeGZZSHo2UDBUY2NuWkRWTFBQVndvVkxhOEE?oc=5","date":"2026-04-07","type":"pipeline","source":"Barchart.com","summary":"Oncolytic Virus Therapies Market: Strong Pharma Growth Forecast Through 2034 – DelveInsight | CG Oncology, Imugene, Amgen, Daiichi Sankyo, Genelux, Replimune, Binhui Biopharma - Barchart.com","headline":"Oncolytic Virus Therapies Market: Strong Pharma Growth Forecast Through 2034 – DelveInsight | CG Oncology, Imugene, Amge","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxQNFUzb0F3T245aDUxQ3ozN20yVjI0M1NoWE8xc2ZXMUZ5T1Z1T1NaU2IzdUNjSENkenM1b0hKbjF4LTVVa1pxbU12emdvUlc5OXRTMDcxcWFjeEtCeU1YNjRwdUhKdDY2amZ0QUxxYUhEN0p5Tm9RUmNGb2RzU2FtT3BSNV93OE9YRXFQRElseXp4aGMyejJIU2tGSQ?oc=5","date":"2026-03-20","type":"pipeline","source":"openPR.com","summary":"Muscle Invasive Bladder Cancer Market Set for Strong Growth - openPR.com","headline":"Muscle Invasive Bladder Cancer Market Set for Strong Growth","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowJBVV95cUxOWnU3YnJCYzNuV0Y1RUFWQXpUYlFDTXhGa1hlMnhGRjAyRy01WXNJc05KSmd3RUVKZmV0aUxXWjVPbkV2dkhwb0s1NFdOWTRKSUVvYW8zdFNGSGJQSG5NMzFVQnB3WC12dS1ZQ3VPQnJ0a3pkVzdfTUlaMmV1bEp4VVJ1YS1QTmRBYlpJOGNYQ0c0M3VFcmZyeVhLTnJQcENYcmdkTHNWSmZiam45YlBwRVI0eHhJNkJPX0ZjdE1mZ2hOX0c5dVRNeUZtOU1LUzNpQjJhZ2NwNmpTQlBoSlh0VmpxbDBaWkZQX05YVmlvMFRzZXc2bnBRd2RrS3hNZFphTVhkT2hCc3BMUlliNHd3bXl3ZnJXa3M5NEFqR1ZNdHlERG_SAaMCQVVfeXFMTlp1N2JyQmMzbldGNUVBVkF6VGJRQ014RmtYZTJ4RkYwMkctNVlzSXNOSkpnd0VFSmZldGlMV1o1T25FdnZIcG9LNTRXTlk0SklFb2FvM3RTRkhiUEhuTTMxVUJwd1gtdnUtWUN1T0JydGt6ZFc3X01JWjJldWxKeFVSdWEtUE5kQWJaSThjWENHNDN1RXJmcnlYS05yUHBDWHJnZExzVkpmYmpuOWJQcEVSNHh4STZCT19GY3RNZmdoTl9HOXVUTXlGbTlNS1MzaUIyYWdjcDZqU0JQaEpYdFZqcWwwWlpGUF9OWFZpbzBUc2V3Nm5wUXdka0t4TWRaYU1YZE9oQnNwTFJZYjR3d215d2ZyV2tzOTRBakdWTXR5RERv?oc=5","date":"2026-02-04","type":"trial","source":"Bolsamania","summary":"Oncolytic Virus Clinical Trial Landscape Gains Momentum: 100+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - Bolsamania","headline":"Oncolytic Virus Clinical Trial Landscape Gains Momentum: 100+ Companies Lead the Charge in Pioneering New Treatments | D","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxNOFpuZGpoQnFodmtVejJJcVRqT2MzaGRoYlFaOXo2VmFudGIyRW1scWhWU1o4eDNsemRqWlZrUFJCYlRobVFuaWhjbV9Md281UHQ3Q2hKc0l5MGw4aF9wd2tMU1pKSEF6Vm14MFBGMFMxZXhySVVSMGV3MUZaYUVUU3A1S2VLN1hBMlNVdXlyWVptRTJTN2RwTmdIcWdRVy1Z0gGgAUFVX3lxTE9aWlE4cWlJMXlJMDFMemdpb1NvVy0xLU5SbEEza0ZUMzZJdldXbEZKNUZnNEhESXpyX0J1YmVfdm1UVjk3bWJ0RWlMUThITE9VckNYYXpXT1ppUkJNNDJJMnJIMGtUMmhRcDVyOEl1cHRuTHZfOGN5TVFPb2xJY1FNS1JQRE82ZFM5QzBFRFNMeWJPa3ZFaVAxQmNZZFExSHM?oc=5","date":"2025-10-02","type":"pipeline","source":"South China Morning Post","summary":"Chinese healthcare, biotech firms flock to Hong Kong for IPOs - South China Morning Post","headline":"Chinese healthcare, biotech firms flock to Hong Kong for IPOs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE9HdlF4RTdSb3pKTkhuT0NIM0FiNHVfSlBvdDlaMk1heE9UT01mQzVCSXZUN0pQWFJSZC1ZM2RrcXNwSkg5SFRDbXFuakQ5R0NVVTZsQVZfZFdPSk5XbEVF?oc=5","date":"2023-03-15","type":"pipeline","source":"Nature","summary":"PF-D-Trimer, a protective SARS-CoV-2 subunit vaccine: immunogenicity and application - Nature","headline":"PF-D-Trimer, a protective SARS-CoV-2 subunit vaccine: immunogenicity and application","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAJBVV95cUxPTnlHZ0xYeFJpOUNPdXF6SW9Mci03eEFjaTdfelpDY3c1Vm9pekxLYU81azdtU2NNTWQtUVR3WDBEV3RSOHR3WndwVHNmeWtFUVo3TUlZdkFkM2FzNzNXa2dNclRQNk1OLXFOcHE3dGV1cWhKZUh4YmYxTmF3NnI5cTlfSTdMS21NNGoxdUZQSW9IZGtwTFBkdWlQYjBzT1FhZFExLXlicmFCbUVCVkU4c1hCQzRhb3RTUTltSjV0ekx6c2lGbnVmZDVuVF9aeHBzNnd3X1MxUUR5c0t2dWFXdjlGVG1CSVFaS3NnZm5vV3NBcnNPb2hrUXA0ejFKTl8waEJ2NWs3NUt0MGEyR0ZuMHlwTS1pVS1VRUowbThLUFZ0c2xrSmhwNzdCRk5aVW1RcGIzOFBMTmdWeWh6?oc=5","date":"2022-07-27","type":"pipeline","source":"prnewswire.com","summary":"BridGene Biosciences Announces $38.5 Million Series B Financing to Further Develop Its Next Generation Chemoproteomics Platform and First-in-Class Oncology Drugs - prnewswire.com","headline":"BridGene Biosciences Announces $38.5 Million Series B Financing to Further Develop Its Next Generation Chemoproteomics P","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}